Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Daewon Pharm. Co., Ltd | Samjin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Daewon Pharm. Co., Ltd | Samjin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Pitavastatin on Bone
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoporosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2024
Lead Product(s) : Pitavastatin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Pitavastatin Tablets
Details : Pitavastatin tablet is a HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in Adult patients with primary hyperlipidemia or mixed dyslipidemia.
Product Name : Livalo-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2023
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Peking University People's Hospital | Wanbang Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 01, 2018
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Peking University People's Hospital | Wanbang Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2016
Lead Product(s) : Pitavastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : JW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2015
Lead Product(s) : Pitavastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pitavastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : National Heart, Lung, and Blood Institute | Kowa Pharmaceuticals America | Gilead Sciences | Massachusetts General Hospital | NEAT ID Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2015
Lead Product(s) : Pitavastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : National Heart, Lung, and Blood Institute | Kowa Pharmaceuticals America | Gilead Sciences | Massachusetts General Hospital | NEAT ID Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable